Loading stock data…
Veracyte (VCYT)
$56.61-1.27 (-2.19%)
Market ClosedLast close Jul 24
Veracyte, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veracyte, Inc. in the Healthcare sector is trading at $56.61 with a market capitalization of $4.1B. Wall Street consensus targets $56.55 (11 analysts), implying a -0.1% move over the next 12 months. The stock is currently near its 52-week high of $60.91, remaining 36.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $139.07M↓ | $140.64M↑ | $131.87M↑ | $130.16M↑ | $114.47M |
| Gross Profit | $101.16M↓ | $101.97M↑ | $91.28M↑ | $89.77M↑ | $79.51M |
| Operating Income | $22.65M↓ | $39.91M↑ | $23.11M↑ | $14.31M↑ | $2.90M |
| Net Income | $28.71M↓ | $41.15M↑ | $19.14M↑ | -$980,000↓ | $7.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.55%
Volume
Today's trading volume
589,509
Recent News
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.